Massimiliano Berretta

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials

Michele Spina, Ulrich Jaeger, Joseph A. Sparano et al. · Blood · 2004 · 190 citations · Full text

Medicine, Oncology, Pharmacology +14

Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial

Marco Trovò, Carlo Furlan, Jerry Polesel et al. · Radiotherapy and Oncology · 2017 · 164 citations

Medicine, Oncology, Radiation Oncology +13

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey

Massimiliano Berretta, Chiara Della Pepa, Paolo Tralongo et al. · Oncotarget · 2016 · 153 citations · Full text

Medicine, Oncology, Cancer Prevention +10

Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma

Michele Spina, Monica Balzarotti, Lilj Uziel et al. · The Oncologist · 2012 · 128 citations · Full text

Medicine, Geriatric Medicine, Oncology +16